IRIDEX Corp Receives Nasdaq Notice for Minimum Bid Price Non-Compliance

What Happened

• IRIDEX Corporation (IRIX) announced in an 8-K filed Sept. 2, 2026 that on August 27, 2026 it received a Nasdaq Notice of Non‑Compliance because the company’s common stock closed below the $1.00 per share minimum for 30 consecutive business days. Nasdaq has given IRIDEX a 180‑calendar‑day cure period, until February 23, 2027, to regain compliance.

Key Details

• Notice date: August 27, 2026; 8‑K filed: September 2, 2026.
• Deficiency: closing bid price under $1.00 for 30 consecutive business days (Nasdaq Listing Rule 5550(a)(2)).
• Cure requirement: closing bid of at least $1.00 per share for 10 consecutive business days during the 180‑day period (ends Feb 23, 2027).
• Possible next steps: if not cured, IRIDEX may be eligible for an additional 180‑day extension if it meets market‑value and other initial listing standards (except the bid price) and files intent to cure (which could include a reverse stock split); failure to regain compliance could lead to delisting and an appeal process.

Why It Matters

• For investors: this is a regulatory compliance risk that could lead to delisting from the Nasdaq Capital Market if not resolved. The company’s stock will continue to trade on Nasdaq during the cure period, but failure to meet the bid‑price requirement or secure an extension could reduce liquidity and investor confidence.
• The filing notes the notice does not affect IRIDEX’s day‑to‑day business operations or SEC reporting obligations. Management said it is monitoring the share price and considering options to regain compliance, but there is no assurance it will succeed.